|Articles|May 1, 2002
- Applied Clinical Trials-05-01-2002
Identifying and Documenting Adverse Events at Clinical Study Sites
Improving adverse event reporting can lead to improved safety profiles and, consequently, fewer drugs pulled from the market.
Advertisement
Articles in this issue
over 24 years ago
Letters to the Editorover 24 years ago
Parents for Orphansover 24 years ago
Fraud, Abuse, and Consentover 24 years ago
Brian Koziolover 24 years ago
A Model-Based Method for Improving Protocol QualityAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Validity, Reliability, and Regulatory Considerations for Consumer Devices in Clinical Research Data Collection
2
ACT Brief: Real-Time Review Ecosystem Approach, AI Infrastructure Before Tools, and FDA Peptide Compounding Access
3
ACT Brief: ESG as Commercial Selection Factor, Real-Time Monitoring Scale Readiness, and FDA Cancer Trial Eligibility Expansion
4
FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility
5